Published in Blood Weekly, November 3rd, 1997
Cangene's manufacturing process of H-BIG will include dual viral inactivation steps using state-of-the-art technology to produce products with the highest safety standards currently available.
Under the terms of the agreement with Cangene, Cangene will manufacture H-BIG for at least three years once the new...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.